HBK Investments’s Cardlytics CDLX Stock Holding History

HBK Investments’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-6,000	Closed	-$878K	–	1028
2018 Q1	$878K	Buy	+6,000	New	+$1.01M	0.01%	650

Other funds holding CDLX

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HBK Investments's CDLX Position: Q2 2018 in Review

HBK Investments sold out of Cardlytics (CDLX) in Q2 2018, closing a stake of 6,000 shares — an estimated $878K sold.

HBK Investments first reported a position in CDLX in Q1 2018 and held it in 1 quarter. The position peaked at $878K in Q1 2018. 53 funds tracked by Wall St. Rank hold CDLX as of Q2 2018.

HBK Investments reported no remaining Cardlytics position as of Q2 2018 after selling out during the quarter.
HBK Investments sold 6,000 Cardlytics shares in Q2 2018, an estimated $878K.
HBK Investments first reported a position in Cardlytics in Q1 2018 and held it in 1 quarter.
HBK Investments's Cardlytics position peaked at $878K in Q1 2018.
53 funds tracked by Wall St. Rank held Cardlytics as of Q2 2018.

Based on HBK Investments's 13F filing for Q2 2018, filed 14 Aug 2018.